Evolent Health (EVH) Faces Downgrade from Canaccord Due to Rising Short-Term Uncertainty and Confusion in Medicare/Medicaid Enrollment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy EVH?
Source: Yahoo Finance
Stock Performance and Price Target Adjustments: Evolent Health Inc. has seen its price targets lowered by Citi and Canaccord, with current targets at $9.50 and $9 respectively, while both firms maintain a Buy rating amid increased uncertainty regarding the company's shares.
Q3 2025 Earnings Report: The company reported $480 million in Q3 revenue, achieving 8% sequential growth and maintaining its full-year revenue guidance between $1.87 and $1.88 billion, ending the quarter with $116.7 million in cash.
Future Revenue Contracts: Evolent Health has secured approximately $2.5 billion in revenue under contract for 2026, including new arrangements expected to contribute over $550 million, utilizing a new performance suite model.
Investment Considerations: While Evolent Health shows potential as an investment, there are suggestions that certain AI stocks may offer better upside potential and lower risk, prompting a recommendation to explore undervalued AI stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVH
Wall Street analysts forecast EVH stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.280
Low
5.00
Averages
9.33
High
16.00
Current: 2.280
Low
5.00
Averages
9.33
High
16.00
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolent Health Appoints New Chief Product Officer
- Leadership Change: Evolent Health has appointed Archie Mayani as Chief Product Officer, bringing over 20 years of leadership experience in health tech and AI, which is expected to accelerate the company's product strategy.
- Innovative Background: Prior to joining Evolent, Mayani served as CPO at GHX, where she pioneered AI-driven capabilities to enhance the resilience of the global healthcare supply chain, providing valuable experience for Evolent's product innovation.
- Performance Enhancement: At Change Healthcare, Mayani focused on innovations in clinical decision support and revenue cycle platforms, helping to reduce administrative burdens for providers and payers, which is anticipated to improve Evolent's product efficiency and market competitiveness.
- Industry Recognition: Mayani has received multiple industry awards, including the Inspiring Leader Award at the 2023 Health 2.0 conference, showcasing her influence and leadership in the healthcare sector, which will enhance Evolent's industry reputation.
See More
Foodsmart Appoints New Board Member to Advance Foodcare in Medicaid
- New Board Member: Foodsmart has appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors, bringing extensive value-based care experience that is expected to drive growth in the Medicaid sector.
- Integration of Nutrition Care: Ajayi emphasizes the critical role of nutrition support within healthcare systems, as Foodsmart aims to improve health outcomes and reduce overall costs for over 3 million members by integrating nutrition care with medical services.
- Advancing Health Equity: Ajayi's appointment will enhance Foodsmart's impact on Medicaid and high-need populations, promoting health equity and ensuring that patients with complex medical needs have access to essential nutrition support.
- Industry Recognition: Ajayi's leadership and innovative models in value-based care have garnered widespread recognition, and her experience will provide valuable strategic guidance for Foodsmart to stand out in a competitive market.
See More
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
Evolent Health Q4 2025 Earnings Call Insights
- Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
- Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
- Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
- Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
See More
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
- Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
- Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
- Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
- Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
See More
Evolent Health Appoints New Chief Product Officer
- Leadership Change: Evolent Health has appointed Archie Mayani as Chief Product Officer, bringing over 20 years of leadership experience in health tech and AI, which is expected to accelerate the company's product strategy.
- Innovative Background: Prior to joining Evolent, Mayani served as CPO at GHX, where she pioneered AI-driven capabilities to enhance the resilience of the global healthcare supply chain, providing valuable experience for Evolent's product innovation.
- Performance Enhancement: At Change Healthcare, Mayani focused on innovations in clinical decision support and revenue cycle platforms, helping to reduce administrative burdens for providers and payers, which is anticipated to improve Evolent's product efficiency and market competitiveness.
- Industry Recognition: Mayani has received multiple industry awards, including the Inspiring Leader Award at the 2023 Health 2.0 conference, showcasing her influence and leadership in the healthcare sector, which will enhance Evolent's industry reputation.
See More
Foodsmart Appoints New Board Member to Advance Foodcare in Medicaid
- New Board Member: Foodsmart has appointed Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, to its Board of Directors, bringing extensive value-based care experience that is expected to drive growth in the Medicaid sector.
- Integration of Nutrition Care: Ajayi emphasizes the critical role of nutrition support within healthcare systems, as Foodsmart aims to improve health outcomes and reduce overall costs for over 3 million members by integrating nutrition care with medical services.
- Advancing Health Equity: Ajayi's appointment will enhance Foodsmart's impact on Medicaid and high-need populations, promoting health equity and ensuring that patients with complex medical needs have access to essential nutrition support.
- Industry Recognition: Ajayi's leadership and innovative models in value-based care have garnered widespread recognition, and her experience will provide valuable strategic guidance for Foodsmart to stand out in a competitive market.
See More
EVOLENT HEALTH: OPPENHEIMER LOWERS PRICE TARGET FROM $12 TO $6
- Stock Price Adjustment: Evolent Health has reduced its target price from $12 to $6.
- Market Impact: This significant cut in target price may reflect changes in market conditions or company performance.
See More
Evolent Health to Participate in Investor Conferences
- Executive Participation: Evolent Health's executive management team will participate in upcoming investor conferences, aiming to enhance the company's transparency and trust in the capital markets through direct interaction with investors.
- Webcast Availability: The events will feature live audio webcasts and replays, allowing investors to access relevant information via Evolent's investor relations website, ensuring timely communication and broad outreach.
- Company Mission: Evolent specializes in achieving better health outcomes for individuals with complex conditions through solutions that simplify and reduce healthcare costs, thereby enhancing its competitive position in the healthcare industry.
- Industry Recognition: Evolent is consistently recognized as one of the top places to work in healthcare nationally, demonstrating its success in attracting and retaining talent, which further solidifies its leadership in the healthcare services sector.
See More
Evolent Health Q4 2025 Earnings Call Insights
- Revenue and EBITDA Performance: Evolent Health reported Q4 2025 revenue of $469 million and adjusted EBITDA of $37.8 million, both exceeding the midpoint of guidance, indicating sustained momentum in organic growth and profitability.
- Future Growth Expectations: CEO Seth Blackley forecasts approximately 30% revenue growth in 2026, with 65% of revenue expected to come from oncology, up from 36% in 2025, highlighting a strategic shift towards high-growth areas.
- Customer and Contract Expansion: The company migrated approximately 90% of Performance Suite revenue under a new model, retaining all key customers and signing two major new clients in the past year, enhancing market competitiveness and customer base.
- Financial Outlook and Challenges: Despite anticipating a $40 million headwind from exchange membership declines, the company plans to achieve $2.5 billion in revenue and $125 million in adjusted EBITDA, demonstrating confidence in future growth.
See More
KeyBanc Downgrades Evolent Health Rating Amid EBITDA Concerns
- Rating Downgrade: KeyBanc Capital Markets downgraded Evolent Health from overweight to sector weight due to concerns over the company's future EBITDA performance, reflecting a cautious market sentiment regarding its profitability.
- Earnings Beat: Despite the Q4 financial results released on the same day exceeding market expectations, analyst Matthew Gillmor noted that EBITDA is expected to be heavily weighted in H2 at 70%, indicating seasonal volatility in the company's earnings.
- Future Outlook: Gillmor also mentioned that the Street EBITDA target for 2027 is expected to be lowered to $187 million, suggesting a decline in market confidence regarding the company's long-term profitability.
- Strong Demand: Despite the downgrade, Evolent's late-stage pipeline remains robust, and high renewal rates with existing customers reflect strong demand among health plans to control specialty costs, particularly in oncology, supporting the company's shift to the PS 2.0 model.
See More
